Literature DB >> 11007451

Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.

K Satyamoorthy1, N H Chehab, M J Waterman, M C Lien, W S El-Deiry, M Herlyn, T D Halazonetis.   

Abstract

Sporadic human tumors and the hereditary cancer predisposition syndrome Li-Fraumeni are frequently associated with mutations in the p53 tumor suppressor gene that compromise its ability to function as a DNA damage checkpoint. A subset of Li-Fraumeni patients with wild-type p53 alleles have mutations in chk2/hcds1, one of the genes signaling the presence of DNA damage to the p53 protein. This suggests that p53 may be kept inactive in human cancer by mutations targeting DNA damage signaling pathways. Melanoma cells are highly radioresistant, yet they express wild-type p53 protein, raising the possibility of defects in the pathways that activate p53 in response to DNA damage. We have described a chk2/hcds1-independent DNA damage signaling pathway that targets Ser-376 within the COOH terminus of p53 for dephosphorylation and leads to increased p53 functional activity. We now report that in several human melanoma cell lines that express wild-type p53, the phosphorylation state of Ser-376 was not regulated by DNA damage. In these cell lines, neither the endogenous wild-type p53 protein nor high levels of ectopic wild-type p53 led to cell cycle arrest or apoptosis. Thus, defective activation of p53 in response to DNA damage may underlie the radioresistance of human melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007451

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  33 in total

1.  New approaches to the biology of melanoma: a workshop of the National Institutes of Health Pathology B Study Section.

Authors:  Meenhard Herlyn; Martin Padarathsingh; Lynda Chin; Mary Hendrix; Dorothea Becker; Mark Nelson; Yves DeClerck; James McCarthy; Suresh Mohla
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Protein kinase Cα (PKCα) regulates p53 localization and melanoma cell survival downstream of integrin αv in three-dimensional collagen and in vivo.

Authors:  Stephen D Smith; Martin Enge; Wenjie Bao; Minna Thullberg; Tânia D F Costa; Helene Olofsson; Behxhet Gashi; Galina Selivanova; Staffan Strömblad
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

3.  SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation.

Authors:  Melissa J Wilking; Chandra Singh; Minakshi Nihal; Weixiong Zhong; Nihal Ahmad
Journal:  Arch Biochem Biophys       Date:  2014-04-18       Impact factor: 4.013

Review 4.  The evolving role of radiation therapy in the management of malignant melanoma.

Authors:  Niloufer Khan; Mohammad K Khan; Alex Almasan; Arun D Singh; Roger Macklis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-12       Impact factor: 7.038

5.  Mechanisms of chromosomal instability in melanoma.

Authors:  William K Kaufmann; Craig C Carson; Bernard Omolo; Adam J Filgo; Maria J Sambade; Dennis A Simpson; Janiel M Shields; Joseph G Ibrahim; Nancy E Thomas
Journal:  Environ Mol Mutagen       Date:  2014-02-24       Impact factor: 3.216

Review 6.  Biological determinants of radioresistance and their remediation in pancreatic cancer.

Authors:  Parthasarathy Seshacharyulu; Michael J Baine; Joshua J Souchek; Melanie Menning; Sukhwinder Kaur; Ying Yan; Michel M Ouellette; Maneesh Jain; Chi Lin; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-02-27       Impact factor: 10.680

7.  The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma.

Authors:  Jing Lin; Qingyuan Yang; Paul T Wilder; France Carrier; David J Weber
Journal:  J Biol Chem       Date:  2010-06-29       Impact factor: 5.157

8.  Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival.

Authors:  Geoffrey E Johnson; Vladimir N Ivanov; Tom K Hei
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

9.  Halofuginone inhibits the establishment and progression of melanoma bone metastases.

Authors:  Patricia Juárez; Khalid S Mohammad; Juan Juan Yin; Pierrick G J Fournier; Ryan C McKenna; Holly W Davis; Xiang H Peng; Maria Niewolna; Delphine Javelaud; John M Chirgwin; Alain Mauviel; Theresa A Guise
Journal:  Cancer Res       Date:  2012-09-20       Impact factor: 12.701

10.  Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression.

Authors:  William K Kaufmann; Kathleen R Nevis; Pingping Qu; Joseph G Ibrahim; Tong Zhou; Yingchun Zhou; Dennis A Simpson; Jennifer Helms-Deaton; Marila Cordeiro-Stone; Dominic T Moore; Nancy E Thomas; Honglin Hao; Zhi Liu; Janiel M Shields; Glynis A Scott; Norman E Sharpless
Journal:  J Invest Dermatol       Date:  2007-06-28       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.